Detection of Intestinal Metaplasia After Successful Eradication of Barrett’s Esophagus with Radiofrequency Ablation

  • Benjamin J. Vaccaro
  • Susana Gonzalez
  • John M. Poneros
  • Peter D. Stevens
  • Kristina M. Capiak
  • Charles J. Lightdale
  • Julian A. Abrams
Original Article

Abstract

Background

Radiofrequency ablation (RFA) is an effective means of eradicating Barrett’s esophagus (BE), both with and without associated dysplasia. Several studies have documented high initial success rates with RFA. However, there is limited data on IM detection rates after eradication.

Aims

To determine the rate of detection of intestinal metaplasia (IM) after successful eradication of Barrett’s esophagus.

Methods

BE patients with and without dysplasia who had undergone RFA were retrospectively identified. Only those who had complete eradication as documented on the initial post-ablation endoscopy, and had minimum two surveillance endoscopies, were included in the analyses. Clinical, demographic, and endoscopic data were collected. Cumulative incidence of IM detection was calculated by the Kaplan–Meier method.

Results

Forty-seven patients underwent RFA and had complete eradication of Barrett’s epithelium. The majority of patients were male (76.6%), and the mean age was 64.2 years. The cumulative incidence of newly detected IM at 1 year was 25.9% (95% CI 15.1–42.1%). Dysplasia was detected at the time of recurrence in four patients, and all cases were detected at the GE junction in the absence of visible BE. Patients with recurrent IM had longer baseline segments of BE (median, 4 cm vs. 2 cm, p = 0.03).

Conclusions

The rate of detection of new IM is high in patients who have undergone successful eradication of BE by RFA. Additionally, dysplasia can recur at the GE junction in the absence of visible BE. Future studies are warranted to identify those patients at increased risk for the development of recurrent intestinal metaplasia.

Keywords

Barrett’s esophagus Endoscopy Therapy Recurrence 

References

  1. 1.
    Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831.PubMedCrossRefGoogle Scholar
  2. 2.
    Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C. The prevalence of Barrett’s esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus. 2010;23:451–457.PubMedCrossRefGoogle Scholar
  3. 3.
    Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677.PubMedCrossRefGoogle Scholar
  4. 4.
    Shaheen NJ, Richter JE. Barrett’s oesophagus. Lancet. 2009;373:850–861.PubMedCrossRefGoogle Scholar
  5. 5.
    Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.PubMedCrossRefGoogle Scholar
  6. 6.
    Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.PubMedCrossRefGoogle Scholar
  7. 7.
    Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol. 2007;102:1154–1161.PubMedCrossRefGoogle Scholar
  8. 8.
    Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy. 2008;40:370–379.PubMedCrossRefGoogle Scholar
  9. 9.
    Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008;68:867–76.Google Scholar
  10. 10.
    Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42:781–789.PubMedCrossRefGoogle Scholar
  11. 11.
    Halsey KD, Chang JW, Greenwald BD. Recurrent disease following endoscopic ablation of Barrett’s neoplasia. Gastroenterology. 2010;138:S17.Google Scholar
  12. 12.
    Shaheen NJ, Fleischer DE, Eisen GM, et al. Durability of epithelial reversion after radiofrequency ablation: follow-up of the AIM Dysplasia Trial. Gastroenterology. 2010;138:S16.Google Scholar
  13. 13.
    Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57:1200–1206.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Benjamin J. Vaccaro
    • 1
  • Susana Gonzalez
    • 1
  • John M. Poneros
    • 1
  • Peter D. Stevens
    • 1
  • Kristina M. Capiak
    • 1
  • Charles J. Lightdale
    • 1
    • 2
  • Julian A. Abrams
    • 1
    • 2
    • 3
  1. 1.Department of MedicineColumbia University Medical CenterNew YorkUSA
  2. 2.Herbert Irving Comprehensive Cancer CenterColumbia UniversityNew YorkUSA
  3. 3.New YorkUSA

Personalised recommendations